1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

07 Mar 2024
Admin
News Article

Ono Pharma Gets in Licensing Agreement for NXI-101

Ono Pharma inks licensing agreement with NEX-I to develop and commercialize NXI-101

Ono Pharmaceutical Co., Ltd., company develops novel therapeutics to help patients live longer, healthier lives, announced that it has entered into a license agreement with NEX-I, Inc. for NXI-101.

About NXI-101

NXI-101 is a first-in-class antibody drug candidate targeting ONCOKINE-1, which is a cancer immunotherapy-resistant factor discovered by NEX-I through its proprietary target screening platform “ONCOKINE platform”. It has a potential to be a novel antibody drug with an efficacy against multiple cancer types including cancer immunotherapy-resistant cancer.

Agreement Terms

Under the terms of this agreement, Ono will have an exclusive right to develop and commercialize NXI-101 and its backup antibodies worldwide.
Ono will pay to NEX-I an up-front and milestone payments on the progress of development and commercialization, as well as tiered royalties based on net sales.

Statement from Ono

“We are pleased to collaborate with NEX-I having a proprietary ONCOKINE platform for development and commercialization of NXI-101. We expect NXI-101 to be a new treatment option for cancer patients,” said Toichi Takino, senior executive officer/executive director, discovery & research of Ono. “Leveraging Ono's experience and expertise in cancer immunotherapy, we will work on the development of the compound to add it to our development pipeline in oncology.""

Words from CEO: NEX-I

“We are delighted to start a journey with Ono, a leader in cancer immunotherapy well-known for its breakthrough anti-PD-1 antibody. This collaboration aligns with NEX-I’s strategic focus on novel target discovery and the advancement of our flagship tumour microenvironment modulator, NXI-101. Through this landmark partnership, we underscore our commitment to identifying and developing novel and differentiated therapies that promise substantial benefits for patients,” said Kyoung Wan Yoon, Ph.D., chief executive officer of NEX-I. “Our alliance with Ono represents a significant step forward for our ONCOKINE platform to assemble a diverse portfolio of clinical candidates across a broad range of mechanisms and therapeutic targets.”

About NEX-I

Founded in 2021, NEX-I, Inc. is a pre-clinical stage Korean biotechnology company pioneering the transformative shift in cancer immunotherapy through its proprietary novel target discovery platform.
NEX-I identifies and counters conventional treatments often facing resistance from evolving cancer cells, and they set new standards to understand the mechanisms of refractory cancers by targeting the causal factors.
With their premier monoclonal antibody, NXI-101, which is designed to modulate the tumour microenvironment by neutralizing the ONCOKINE-1, increasing immune susceptibility of the cancer patients can be expected.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!